TY - JOUR T1 - IGF Bioregulation System in Benign and Malignant Thyroid Nodular Disease: A Systematic Review JF - In Vivo JO - In Vivo SP - 3069 LP - 3091 DO - 10.21873/invivo.12141 VL - 34 IS - 6 AU - APOSTOLOS KARAGIANNIS AU - EVA KASSI AU - ANTONIOS CHATZIGEORGIOU AU - MICHAEL KOUTSILIERIS Y1 - 2020/11/01 UR - http://iv.iiarjournals.org/content/34/6/3069.abstract N2 - Background/Aim: The insulin-like growth factor bioregulation system is implicated in cancer biology. Herein, we aim to review the evidence on the expression of the insulin-like growth factor 1 and 2 (IGF1 and IGF2), their receptors (IGF-Rs) and IGF-binding proteins (IGFBPs) in thyroid tissue and their possible association with benign and malignant thyroid nodular diseases. Materials and Methods: We systematically reviewed Pubmed and Scopus databases up to May 2020. A total of 375 articles were retrieved and analyzed. Results: Among 375 articles, 45 were included in this systematic review study. IGF1 was investigated in 31 studies, IGF2 in 1, IGF1 receptor in 15 and IGF-binding proteins in 13 articles. IGF1 expression in humans was dependent on the number and compound of benign nodules as well as the method of measurement. In differentiated thyroid carcinoma, a positive correlation between IGF1 and immunohistological stage was documented in some studies while in others only a positive trend was observed. IGF-1R and IGFBPs expression was higher in malignant rather than benign lesions. There was only a positive trend for increased IGF2 expression in malignancy, while IGFBPs were in most studies statistically increased in various cancer types compared to benign nodular disease. Conclusion: The present data demonstrate that in most studies there is statistically positive expression of IGF-1 and less of IGF-2 in thyroid cancer compared to normal thyroid tissue. ER -